Editorial: Cardiorenal dysregulation in endocrine disorders: innovative mechanisms and therapeutic interventions.
作者信息
Shawky Noha M, Soliman Eman, Abdel-Rahman Abdel A, Rezq Samar
机构信息
Department of Pharmacology and Toxicology, Mississippi Center of Excellence in Perinatal Research, Women's Health Research Center, Cardiovascular Renal Research Center, University of Mississippi Medical Center, Jackson, MS, United States.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
出版信息
Front Pharmacol. 2023 Aug 25;14:1275919. doi: 10.3389/fphar.2023.1275919. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Cardiorenal dysregulation in endocrine disorders: innovative mechanisms and therapeutic interventions.
Front Pharmacol. 2023 Aug 25;14:1275919. doi: 10.3389/fphar.2023.1275919. eCollection 2023.
2
Autophagy: a housekeeper in cardiorenal metabolic health and disease.
Biochim Biophys Acta. 2015 Feb;1852(2):219-24. doi: 10.1016/j.bbadis.2014.06.025. Epub 2014 Jun 28.
3
Neurohormonal, Endocrine, and Immune Dysregulation and Inflammation in Cardiorenal Syndrome.
Cardiorenal Med. 2019;9(5):265-273. doi: 10.1159/000500715. Epub 2019 Jul 2.
4
Immunomodulatory Approaches in Diabetes-Induced Cardiorenal Syndromes.
Front Cardiovasc Med. 2021 Jan 28;7:630917. doi: 10.3389/fcvm.2020.630917. eCollection 2020.
5
Sirtuin 7 serves as a promising therapeutic target for cardiorenal diseases.
Eur J Pharmacol. 2022 Jun 15;925:174977. doi: 10.1016/j.ejphar.2022.174977. Epub 2022 May 2.
6
Acute decompensated heart failure and the cardiorenal syndrome.
Crit Care Med. 2008 Jan;36(1 Suppl):S75-88. doi: 10.1097/01.CCM.0000296270.41256.5C.
7
Role of autophagy in inherited metabolic and endocrine myopathies.
Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):48-55. doi: 10.1016/j.bbadis.2018.10.023. Epub 2018 Oct 18.
8
miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome.
Front Pharmacol. 2020 May 15;11:726. doi: 10.3389/fphar.2020.00726. eCollection 2020.
9
Soluble tumor necrosis factor receptor type 1 predicts cardiorenal outcomes and better associated with distinct cardiovascular or renal outcomes than precedential renal or cardiovascular events in type 2 diabetes mellitus.
Ther Adv Endocrinol Metab. 2023 Oct 29;14:20420188231207345. doi: 10.1177/20420188231207345. eCollection 2023.
10
RAAS inhibition and cardiorenal syndrome.
Curr Hypertens Rev. 2014;10(2):107-11. doi: 10.2174/1573402111666141231144228.
本文引用的文献
1
The endocrinological component and signaling pathways associated to cardiac hypertrophy.
Mol Cell Endocrinol. 2020 Dec 1;518:110972. doi: 10.1016/j.mce.2020.110972. Epub 2020 Aug 7.
2
Chinese Medicinal Leech: Ethnopharmacology, Phytochemistry, and Pharmacological Activities.
Evid Based Complement Alternat Med. 2016;2016:7895935. doi: 10.1155/2016/7895935. Epub 2016 May 4.
3
Myocardial ischemia reperfusion injury: from basic science to clinical bedside.
Semin Cardiothorac Vasc Anesth. 2012 Sep;16(3):123-32. doi: 10.1177/1089253211436350. Epub 2012 Feb 23.
4
Insulin attenuates myocardial ischemia/reperfusion injury via reducing oxidative/nitrative stress.
Am J Physiol Endocrinol Metab. 2010 Apr;298(4):E871-80. doi: 10.1152/ajpendo.00623.2009. Epub 2010 Feb 2.
5
Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury.
Am J Physiol Endocrinol Metab. 2010 Mar;298(3):E663-70. doi: 10.1152/ajpendo.00663.2009. Epub 2009 Dec 22.
6
Effect of estrogen on global myocardial ischemia-reperfusion injury in female rats.
Am J Physiol Heart Circ Physiol. 2000 Dec;279(6):H2766-75. doi: 10.1152/ajpheart.2000.279.6.H2766.
7
Myocardial ischemia-reperfusion injury in estrogen receptor-alpha knockout and wild-type mice.
Am J Physiol Heart Circ Physiol. 2000 May;278(5):H1640-7. doi: 10.1152/ajpheart.2000.278.5.H1640.
8
Effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury: an overview.
Basic Res Cardiol. 1993;88 Suppl 1:155-67. doi: 10.1007/978-3-642-72497-8_11.
Zotero 插件